NEO
HOLD / NEUTRALNeutralComposite
57.20
Technical
79.50
Fundamental
42.30
Rank
—
Price
13.40
Hurst
0.54
As of
Jul 29, 2026
Daily
NeoGenomics, Inc.
HealthcareDiagnostics & ResearchNeoGenomics operates diagnostic laboratories specializing in cancer testing across the United States and United Kingdom. The company provides various laboratory services to healthcare providers, research institutions, and pharmaceutical firms, including chromosomal analysis, genetic sequencing, cell characterization, protein detection, and microscopic cell examination. Its testing capabilities support both clinical diagnosis and pharmaceutical development programs in oncology.
Market cap
$2.6B
P/E (trailing)
—
P/E (forward)
58.81
PEG ratio
2.09
Dividend yield
—
Beta
1.75
52w range
7.07 – 19.89
Return on equity
-6.33%
Profit margin
-6.77%
Revenue growth
+11.20%
Earnings growth
—
Price history
1Y: 18.94 (+119.7%) · range 7.19–18.94
Cycle position
72/ 100 cycle scoreAPPROACHING EXIT
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 0 · NOT READY · exit proximity 35
Conviction
26/ 100 · maturity 100%
VScore.4037
Buildup.2027
EMA entry setup.250
Fundamentals.1542
Volume profile
POC
8.47
Price vs POC
+123.7%
Overhead supply
2%
Runway
open sky
Value area 7.07–14.94 · 2% of 120d volume overhead · clean runway
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trend-signal | 0.668 | Aug 28, 2026 |
| squeeze-risk | 0.401 | Sep 17, 2026 |
| short-interest | 0.400 | Sep 17, 2026 |
| congressional-trading | 0.000 | Sep 17, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +13.75% | +13.75% | mature |
| 40d | +13.43% | +22.07% | 31/40d |